Drugs / TAC-302
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03175029 | Sep 2017 → Nov 2019 | overactive bladder | Taiho Pharmaceutical Co., Ltd. | Completed | Mixed |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAC-302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03175029 ↗ |
| Route | Oral | “patients were randomized 2:1 to receive oral TAC-302 200 mg or placebo twice daily for 12 weeks.” PMID 36205739 ↗ Oct 2022 |